Site icon pharmaceutical daily

Global Postoperative Pain Pipeline Market Research Report 2022: Comprehensive Insights about 55+ Companies and 55+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Postoperative Pain – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Postoperative Pain pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postoperative Pain pipeline landscape is provided which includes the disease overview and Postoperative Pain treatment guidelines. The assessment part of the report embraces, in depth Postoperative Pain commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postoperative Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Postoperative Pain R&D. The therapies under development are focused on novel approaches to treat/improve Postoperative Pain.

Postoperative Pain Emerging Drugs Chapters

This segment of the Postoperative Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Postoperative Pain Emerging Drugs

VVZ-149: Vivozon

VVZ-149 is a new mechanism-based non-narcotic and non-NSAID analgesic demonstrating the robust (comparable to morphine) pain-suppressing efficacy in a panel of in vivo models (post-operative, formalin-induced or neuropathic pain model). The compound has also shown the anti-itching effect in the serotonin-induced itching model. These in vivo efficacies are attributed to the synergistic or additive dual antagonistic activity of VVZ-149 against GlyT2 and 5HT2A which are key receptors for the transmission of the pain signal in spinal dorsal horn area and/or peripheral sensory neurons.

Qutenza: Grunenthal

Qutenza (capsaicin) 8% topical system is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. It is currently in Phase III stage of development for the treatment of Post-surgical neuropathic pain.

CYT-1010: Cytogel Pharma

CYT-1010 is the first member of a new class of drugs, the endomorphins, to reach clinical development. It produces pain relief through a novel mechanism of action on the endomorphin (EM) receptor. CYT-1010, is entering Phase II clinical development, following a successful Phase I study in humans. This breakthrough pain medicine has shown reduced potential for addiction and significantly less risk of respiratory depression, relative to treatment with traditional pain medicines.

ACP-044: ACADIA Pharmaceuticals

ACP-044 is a novel, first-in-class, orally administered, non-opioid analgesic. The mechanism of action is thought to interrupt multiple pain pathways and sensitization of neurons to pain, by accelerating the decomposition of peroxynitrite, a by-product of tissue damage. A Phase II study was initiated evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery in March 2021.

CAM2048: Camurus

CAM2048 is a buprenorphine depot formulation for the treatment of postoperative pain providing rapid onset of action and therapeutic buprenorphine plasma levels over a couple of days. CAM2048 is being developed in collaboration with Braeburn Pharmaceuticals and has been successfully evaluated in a completed Phase I trial. The drug is currently being evaluated in Phase I/II stage of development.

ST 2427: SiteOne Therapeutics

ST-2427 is an experimental intravenous, non-opioid analgesic for the management of moderate-to-serve severe pain. ST-2427 blocks sodium ion channel 1.7 (NaV1.7). NaV1.7 is a type of sodium channel that is highly expressed in peripheral nerve fibers that play a critical role in the generation and conduction of pain signals.

As ST-2427 does not enter the brain, it is not expected to cause the central nervous system adverse effects (e.g. sedation, nausea, dependence and addition) that plague existing pain therapeutics such as the opioids. The development of ST-2427 was supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) under Award Number UG3DA049599.

Key Questions

Key Players

Key Products

Key Topics Covered:

Introduction

Executive Summary

Postoperative Pain: Overview

Pipeline Therapeutics

Therapeutic Assessment

Late Stage Products (Phase III)

VVZ-149: Vivozon

Mid Stage Products (Phase II)

TLC590: Taiwan Liposome Company

Early Stage Products (Phase I)

ST 2427: SiteOne Therapeutics

Preclinical and Discovery Stage Products

INSB200: InSitu Biologics

Inactive Products

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lgu4qs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version